Nivolumab and Cabozantinib in People with HIV and Advanced Solid Tumors: A Pilot Trial and Systematic Review. (PubMed, Oncologist) - Oct 9, 2026 - P1 | "Nivolumab plus cabozantinib had a manageable safety profile without an apparent loss of HIV virologic control in available measurements. Durable disease stabilization occurred in some participants, but antitumor efficacy cannot be determined from this small, heterogeneous cohort. These findings support larger dedicated studies in PWH, particularly in Kaposi sarcoma."
Journal • Genito-urinary Cancer • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Prostate Cancer • Sarcoma • Solid Tumor • CD4
|
|
Balazs Halmos; Benjamin A Gartrell; Chaoyuan Kuang; Ece Cali; Haiying Cheng; Hong Wang; Joseph Sparano; Lakshmi Rajdev; Liza C Villaruz; Melissa A Burgess; Missak Haigentz; Mumtu Lalla; Seth Michaels Pollack; Shuai Wang; Xiaonan Xue
|